Prevalence of cognitive and functional impairment in a community sample from São Paulo, Brazil.

AIMS: To present the prevalence of cognitive and functional impairment (CFI) in community-dwelling elderly subjects from the city of São Paulo. METHODS: The population was aged 60 years and older (n = 1,563; 68.7% women and 31.3% men) and lived in different socioeconomic areas. The following instruments were administered to the elderly: the Mini Mental State Examination and the Fuld Object Memory Evaluation. The Informant Questionnaire on Cognitive Decline in the Elderly and the Bayer-Activities of Daily Living scale were administered to an informant. RESULTS: The prevalence of CFI (n = 250) was 16% (95% confidence interval, CI: 14.2-17.8%) or 15.8% (95% CI: 13.8-17.8%). In regression models, the increase in the odds ratio (OR) of CFI was associated with age, for elderly individuals aged 75 years or older, illiterates or with 1-4 years of schooling, and with a history of stroke and diabetes mellitus. On the other hand, for subjects with a tumor history, the OR of CFI was significantly reduced. CONCLUSION: CFI was high and increased at older ages and in subjects with low education. Potentially changeable factors were identified (stroke and diabetes), and the possible 'protective effect' of tumor/cancer against CFI should be further investigated by longitudinal studies.

The Bayer: Activities of Daily Living Scale (B-ADL) in the differentiation between mild to moderate dementia and normal aging.

OBJECTIVES: To investigate the applicability of the Bayer - Activities of Daily Living scale and its efficiency in differentiating individuals with mild to moderate dementia from normal elderly controls. METHOD: We selected 33 patients with diagnosis of mild to severe dementia, according to ICD-10 criteria, and 59 controls. All the subjects were evaluated with the Mini-Mental State Examination and the Clinical Dementia Rating Scale and the Bayer - Activities of Daily Living scale was applied to informants. RESULTS: The internal consistency of the Bayer - Activities of Daily Living was high (Cronbach's alpha = 0.981). Mean Mini-Mental State Examination and Bayer - Activities of Daily Living scores of demented patients and controls were significantly different (p < 0.001). Mean Mini-Mental State Examination and Bayer - Activities of Daily Living scores were significantly different between Clinical Dementia Rating Scale 0 (controls; n = 59) versus Clinical Dementia Rating Scale 1 (mild dementia; n = 15), Clinical Dementia Rating Scale 0 versus Clinical Dementia Rating Scale 2 (moderate dementia; n = 13), and for Clinical Dementia Rating Scale 1 versus Clinical Dementia Rating Scale 2 (p < 0.003). DISCUSSION: The Bayer - Activities of Daily Living scale and Mini-Mental State Examination differentiated elderly controls from patients with mild or moderate dementia, and patients with mild dementia from those with moderate dementia. CONCLUSIONS: The results suggest that the Bayer - Activities of Daily Living scale applied to an informant can help in the diagnosis and follow-up of Brazilian patients with mild to moderate dementia.

[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report]. / Reabilitação cognitiva em pacientes com doença de Alzheimer: Relato de trabalho em equipe multidisciplinar.

OBJECTIVE: This study aims to show preliminary results of the 'combined treatment' (acetylcholinesterase inhibitor + cognitive training) on a group of mild Alzheimer's disease (AD) patients, followed-up for 7 months. METHODS: Six mild AD patients, diagnosed according to ICD-10 and NINCDS-ADRDA criteria, were included on a open trial with Rivastigmine, 6-12 mg/day, for 2 months, followed by a weekly cognitive rehabilitation group, for 5 months. Caregivers were submitted to a weekly group of counseling and support for 5 months. RESULTS: Stabilization or mild improvement of patients' cognitive and activities of daily living deficits were found, besides reduction of patients and caregivers' depressive and anxiety levels. CONCLUSION: The 'combined treatment' can help on the stabilization or result on a mild improvement of AD patients' cognitive and functional deficits. Support and counseling interventions can reduce the levels of caregivers' psychiatric symptoms.

Prevalence of cognitive and functional impairment in a community sample in Ribeirão Preto, Brazil.

OBJECTIVE: This study aimed at estimating the prevalence of cognitive and functional impairment (CFI) in a community sample in Ribeirão Preto, Brazil, evaluating its distribution in relation to various socio-demographic and clinical factors. METHODS: The population was a representative sample aged 60 and older, from three different socio-economic classes. Cluster sampling was applied. Instruments used to select CFI (a syndromic category that does not exclude dementia): 'Mini Mental State Examination' (MMSE), 'Fuld Object Memory Evaluation' (FOME), 'Informant Questionnaire on Cognitive Decline in the Elderly' (IQCODE), 'Bayer Activities of Daily Living Scale' (B-ADL) and clinical interviews. The data obtained were submitted to bivariate and logistic regression analysis. RESULTS: A sample of 1.145 elderly persons was evaluated, with a mean age of 70.9 years (60-100; DP: 7.7); 63.4% were female, and 52.8% had up to 4 years of schooling. CFI prevalence was 18.9% (n = 217). Following logistic regression analysis, higher age, low education, stroke, epilepsy and depression were associated with CFI. Female sex, widowhood, low social class and head trauma were associated with CFI only on bivariate analysis. CONCLUSION: CFI prevalence results were similar to those found by studies in Brazil, Puerto Rico and Malaysia. Cognitive and functional impairment is a rather heterogeneous condition which may be associated with various clinical conditions found in the elderly population. Due to its high prevalence and association with higher mortality and disability rates, this clinical syndrome should receive more attention on public health intervention planning.

Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study.

OBJECTIVE: To study the efficacy of cognitive rehabilitation combined with acetylcholinesterase inhibitor (AChE-I) treatment in patients with mild Alzheimer's disease and their relatives. METHOD: Thirteen patients with mild Alzheimer's disease treated with rivastigmine 6-12 mg/day for more than two months started cognitive rehabilitation training. Before and after the cognitive rehabilitation training patients were assessed through cognitive tests, activities of daily living scale, neuropsychological battery and scales to evaluate caregivers' depressive and anxiety symptoms. Six patients were randomized to a combined treatment group (AChE-I plus cognitive rehabilitation and caregiver support) and seven patients to a control group (AChE-I only) and followed up for five months. RESULTS: Mini-Mental State Examination (MMSE) scores (p = 0.047) and backward digit span scores (p = 0.018) were significantly different between the groups on follow-up. The combined treatment group showed a better positive treatment effect on cognitive and neuropsychological tests applied to patients and reduction of psychiatric symptoms was observed in their caregivers (nonsignificant). CONCLUSION: Cognitive rehabilitation associated with AChE-I treatment can potentially be useful to stabilize or improve cognitive and functional performance of patients with mild Alzheimer's disease and can reduce caregivers' psychiatric symptoms.

The Bayer: Activities of Daily Living Scale (B-ADL) in the differentiation between mild to moderate dementia and normal aging

OBJECTIVES: To investigate the applicability of the Bayer - Activities of Daily Living scale and its efficiency in differentiating individuals with mild to moderate dementia from normal elderly controls. METHOD: We selected 33 patients with diagnosis of mild to severe dementia, according to ICD-10 criteria, and 59 controls. All the subjects were evaluated with the Mini-Mental State Examination and the Clinical Dementia Rating Scale and the Bayer - Activities of Daily Living scale was applied to informants. RESULTS: The internal consistency of the Bayer - Activities of Daily Living was high (Cronbach's alpha = 0.981). Mean Mini-Mental State Examination and Bayer - Activities of Daily Living scores of demented patients and controls were significantly different (p < 0.001). Mean Mini-Mental State Examination and Bayer - Activities of Daily Living scores were significantly different between Clinical Dementia Rating Scale 0 (controls; n = 59) versus Clinical Dementia Rating Scale 1 (mild dementia; n = 15), Clinical Dementia Rating Scale 0 versus Clinical Dementia Rating Scale 2 (moderate dementia; n = 13), and for Clinical Dementia Rating Scale 1 versus Clinical Dementia Rating Scale 2 (p < 0.003). DISCUSSION: The Bayer - Activities of Daily Living scale and Mini-Mental State Examination differentiated elderly controls from patients with mild or moderate dementia, and patients with mild dementia from those with moderate dementia. CONCLUSIONS: The results suggest that the Bayer - Activities of Daily Living scale applied to an informant can help in the diagnosis and follow-up of Brazilian patients with mild to moderate dementia.

OBJETIVOS: Investigar a aplicabilidade da escala Bayer - Atividades de Vida Diária e sua eficiência em diferenciar indivíduos com demência leve a moderada de indivíduos normais. MÉTODO: Foram selecionados 33 pacientes com diagnóstico de demência leve a grave, de acordo com os critérios da CID-10, e 59 controles. Todos os indivíduos foram avaliados pelo Mini-Exame do Estado Mental e pela Escala de Avaliação Clínica de Demência e os informantes responderam à Bayer - Atividades de Vida Diária. RESULTADOS: A consistência interna da Bayer - Atividades de Vida Diária foi alta (Cronbach Alpha = 0,981). A pontuação média do Mini-Exame do Estado Mental e da Bayer - Atividades de Vida Diária foi significativamente diferente entre os pacientes com demência e o grupo controle (p < 0,001). Os valores do Mini-Exame do Estado Mental e da Bayer - Atividades de Vida Diária foram significativamente diferentes entre a Escala de Avaliação Clínica de Demência 0 (controles; n = 59) e a Escala de Avaliação Clínica de Demência 1 (demência leve; n = 15), a Escala de Avaliação Clínica de Demência 0 e a Escala de Avaliação Clínica de Demência 2 (demência moderada; n = 13) e entre a Escala de Avaliação Clínica de Demência 1 e a Escala de Avaliação Clínica de Demência 2 (p < 0,003). DISCUSSÃO: A Bayer - Atividades de Vida Diária e o Mini-Exame do Estado Mental diferenciaram controles idosos de pacientes com demência leve ou moderada, e pacientes com demência leve daqueles com demência moderada. CONCLUSÕES: Os resultados sugerem que a Bayer - Atividades de Vida Diária, aplicada aos cuidadores, é um instrumento que pode ajudar no diagnóstico e seguimento de pacientes brasileiros com demência leve a moderada.

Reabilitaçäo cognitiva em pacientes com doença de Alzheimer: Relato de trabalho em equipe multidisciplinar / Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report

OBJETIVO: Apresentar resultados preliminares do 'tratamento combinado' (inibidor da acetilcolinesterase + treinamento cognitivo), em um grupo de pacientes com doença de Alzheimer (DA) leve, acompanhados por 7 meses. MÉTODO: Seis pacientes com diagnóstico de DA leve, de acordo com critérios diagnósticos da CID-10 e NINCDS-ADRDA, foram submetidos a ensaio clínico aberto com Rivastigmina, 6-12 mg/dia, por 2 meses, seguido por grupo de reabilitaçäo cognitiva semanal, por 5 meses. Os familiares/cuidadores foram atendidos em grupo semanal de suporte e aconselhamento, por 5 meses. RESULTADOS: Ao final do acompanhamento, houve: estabilizaçäo ou discreta melhora dos déficits cognitivos e das atividades de vida diária dos pacientes; estabilizaçäo ou reduçäo dos níveis de depressäo e ansiedade nos pacientes e familiares. CONCLUSÄO: O 'tratamento combinado' pode auxiliar na estabilizaçäo ou resultar em leve melhora dos déficits cognitivos e funcionais de pacientes com DA leve. As intervençöes de suporte e aconselhamento podem reduzir o nível de sintomas psiquiátricos de seus familiares. PALAVRAS-CHAVE: demência, doença de Alzheimer, inibidor da acetilcolinesterase, reabilitaçäo cognitiva, atividades de vida diária, cuidadores